mRNA COVID vaccines appear to make immunotherapy cancer drugs work better

Among 180 such patients with advanced non-small cell lung cancer who received an mRNA-based COVID vaccine from Moderna or Pfizer/BioNTech , the median survival, or the point at which half the patients had died, was 37.33 months. Among 704 cancer patients who did not receive an mRNA COVID shot, median survival was 20.6 months.